Catalyst Biosciences, inventor of Alterase™ therapeutics, has secured two big deals: one with Wyeth for hemophilia products including the lead product, CB 813, and another deal with MedImmune to develop drug candidates against two targets, of which one will address inflammatory and autoimmune diseases.